NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk
Amedeo Lonardo, Fabio Nascimbeni, Stefano Ballestri – 13 January 2017
Augmenter of liver regeneration: A fundamental life protein
Michael A. Nalesnik, Chandrashekhar R. Gandhi, Thomas E. Starzl – 13 January 2017
Comment on “esophageal balloon tamponade vs. esophageal stent in controlling acute refractory variceal bleeding: A multicenter RCT”
Felix Gundling, Maximilian Tiller, Wolfgang Schepp – 11 January 2017
Idiosyncratic drug‐induced liver injury associated with bile duct loss and vanishing bile duct syndrome: Rare but has severe consequences
Einar S. Björnsson, Jon Gunnlaugur Jonasson – 10 January 2017
CCBE1 mutation causing sclerosing cholangitis: Expanding the spectrum of lymphedema‐cholestasis syndrome
André Viveiros, Marion Reiterer, Benedikt Schaefer, Armin Finkenstedt, Stefan Schneeberger, Hubert Schwaighofer, Patrizia Moser, Rudolf Sprenger, Bernhard Glodny, Wolfgang Vogel, Andreas R. Janecke, Heinz Zoller – 10 January 2017 – A 52‐year old patient presented with lymphedema, protein loosing enteropathy, and sclerosing cholangitis and was diagnosed with lymphedema cholestasis syndrome (LCS).
Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma
Xihua Yue, Jing Ai, Yang Xu, Yi Chen, Min Huang, Xinying Yang, Bo Hu, Haotian Zhang, Changxi He, Xinrong Yang, Weiguo Tang, Xia Peng, Liwei Dong, Hongyang Wang, Jia Fan, Jian Ding, Meiyu Geng – 10 January 2017 – Deregulation of the immune system is believed to contribute to cancer malignancy, which has led to recent therapeutic breakthroughs facilitating antitumor immunity. In a malignant setting, immunoglobulin receptors, which are fundamental components of the human immune system, fulfill paradoxical roles in cancer pathogenesis.
Portosystemic collaterals in living donor liver transplantation: What is all the fuss about?
Mettu Srinivas Reddy, Mohamed Rela – 10 January 2017 – Portosystemic collaterals are a common finding in patients with cirrhosis undergoing liver transplantation. Recently, there has been a renewed interest regarding their significance in the setting of living donor liver transplantation (LDLT) due to concerns of graft hypoperfusion or hyperperfusion and its impact on early posttransplant outcomes.
CCBE1 mutation causing sclerosing cholangitis: Expanding the spectrum of lymphedema‐cholestasis syndrome
André Viveiros, Marion Reiterer, Benedikt Schaefer, Armin Finkenstedt, Stefan Schneeberger, Hubert Schwaighofer, Patrizia Moser, Rudolf Sprenger, Bernhard Glodny, Wolfgang Vogel, Andreas R. Janecke, Heinz Zoller – 10 January 2017 – A 52‐year old patient presented with lymphedema, protein loosing enteropathy, and sclerosing cholangitis and was diagnosed with lymphedema cholestasis syndrome (LCS).
A liver‐specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis
Biljana Atanasovska, Sander S. Rensen, Marijke R. Sijde, Glenn Marsman, Vinod Kumar, Iris Jonkers, Sebo Withoff, Ronit Shiri‐Sverdlov, Jan Willem M. Greve, Klaas Nico Faber, Han Moshage, Cisca Wijmenga, Bart van de Sluis, Marten H. Hofker, Jingyuan Fu – 10 January 2017 – Hepatocyte apoptosis in nonalcoholic steatohepatitis (NASH) can lead to fibrosis and cirrhosis, which permanently damage the liver. Understanding the regulation of hepatocyte apoptosis is therefore important to identify therapeutic targets that may prevent the progression of NASH to fibrosis.
Activation of the c‐Jun N‐terminal kinase pathway aggravates proteotoxicity of hepatic mutant Z alpha1‐antitrypsin
Nunzia Pastore, Sergio Attanasio, Barbara Granese, Raffaele Castello, Jeffrey Teckman, Andrew A. Wilson, Andrea Ballabio, Nicola Brunetti‐Pierri – 10 January 2017 – Alpha1‐antitrypsin deficiency is a genetic disease that can affect both the lung and the liver. The vast majority of patients harbor a mutation in the serine protease inhibitor 1A (SERPINA1) gene leading to a single amino acid substitution that results in an unfolded protein that is prone to polymerization.